Dialog Box


What is new ?

This information is about some of the newer, targeted drug treatments for lymphoma that are starting to be used or have been recently approved for use in people with lymphoma.

Note that the drugs described here are new treatments, so information about the possible side effects, including late effects (side effects that can occur months or years after treatment is finished), is still being gathered. Your team should discuss the most up-to-date information with you if you are going to be treated with any of these drugs.

ABT – 199 (Venetoclax)

ABT-199, also known as Venetoclax was discovered by an Australian team of Melbourne-based researchers, shows great promise for people with different subtypes of lymphoma.

Venetoclax is a targeted therapy medicine used in the treatment of CLL with a promising outlook in treatment of other subtypes of lymphoma in the future. Venetoclax works by targeting a specific protein in your blood called BCL-2 which is a protein that may build up in your body when you have CLL and prevent CLL cells from selfdestruction naturally.
Venetoclax is an oral tablet that you take every day.

Venetoclax may have the following side effects:
• Diarrhoea
• Lowered blood counts
• Nausea
• Tiredness
• Upper respiratory tract infection

Venetoclax is approved by the TGA and is being considered for listing and approval with the PBS.